文献速递真菌感染

侵袭性霉菌病SECURE试验中艾沙康唑血药浓度的变异性和暴露-效应关系

Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

该分析基于SECURE试验,评估艾沙康唑血药浓度在受试者间和采样时间点的变异性及其与结局的关系。结果显示谷浓度分布相似,样本间平均变异系数23.2%,未观察到浓度依赖的疗效或安全性关系。

要点

  • 艾沙康唑谷浓度在受试者间和采样时间点间变异有限,样本间平均变异系数23.2%。
  • 未观察到血药浓度与疗效(42天全因死亡率、治疗结束时总体反应)或安全性存在依赖关系。
  • 85/97例受试者首次与后续样本浓度差异小于2倍。

核心结论

  • 艾沙康唑血药浓度在受试者间和采样时间点间 reasonably consistent,且与结局差异无关。

研究设计与样本

  • SECURE试验中接受艾沙康唑治疗(372 mg硫酸艾沙康唑鎓,相当于200 mg艾沙康唑,每日三次用2天,之后每日一次)的侵袭性真菌病受试者。
  • 分析集1:所有确诊/临床诊断/疑似IFD且至少接受1剂艾沙康唑的受试者样本(160例)。
  • 分析集2:分析集1中提供>1个样本的受试者(97例)。
  • 分析集3:分析集1中确诊/临床诊断侵袭性曲霉病的受试者(98例)。

主要发现

  • 分析集1、2、3的谷浓度分布相似,均值(SD)分别为3406.6(1511.5)、3495.6(1503.3)和3368.1(1523.2)ng/mL。
  • 分析集2中样本间平均变异系数为23.2%;85/97例受试者首次与后续样本浓度差异<2倍。
  • 按受试者数据四分位分组,未观察到疗效或安全性的浓度依赖关系。

临床怎么用

  • 基于SECURE试验数据,艾沙康唑血药浓度与疗效和安全性无关,常规治疗药物监测可能并非必需。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This analysis evaluated the variability of isavuconazole plasma concentrations between subjects and between sampling times, and assessed their relationship to outcomes for subjects with invasive fungal disease (IFD) in the SECURE trial. METHODS: Isavuconazole-treated subjects received 372 mg of isavuconazonium sulphate (corresponding to 200 mg of isavuconazole) three times daily for 2 days, then once daily. Plasma samples were collected after day 4 and analysis sets were constructed as follows: analysis set 1 included all samples from subjects with proven/probable/possible IFD who received ≥1 dose of isavuconazole; analysis set 2 included samples from subjects in analysis set 1 who had provided >1 sample; and analysis set 3 included samples from subjects in analysis set 1 with proven/probable invasive aspergillosis. Assessments included overall distributions of plasma concentrations and variability between samples (analysis sets 1 and 2) as well as relationships to outcomes [all-cause mortality (day 42), overall response (end of treatment) and treatment-emergent adverse events; analysis sets 1 and 3]. RESULTS: Analysis sets 1, 2 and 3 included samples from 160, 97 and 98 subjects, respectively. Trough concentrations for each were distributed similarly [mean (SD): 3406.6 (1511.5), 3495.6 (1503.3) and 3368.1 (1523.2) ng/mL, respectively]. The mean coefficient of variation between samples in analysis set 2 was 23.2%; differences between concentrations in first samples and subsequent samples were <2-fold for 85/97 subjects. In quartiles of subject data, no concentration-dependent relationships were observed for efficacy or safety. CONCLUSIONS: Plasma concentrations of isavuconazole were reasonably consistent between subjects and sampling times, and were not associated with differences in outcomes.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Kaindl T, Andes D, Engelhardt M, et al. Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases. J Antimicrob Chemother. 2019. PMID: 30476108. doi:10.1093/jac/dky463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。